FDA-authorized profile

Rho

16 Bit Inc · X-ray/Radiography · FDA-authorized (De Novo)

Authorized purpose: Rho analyzes standard frontal radiographs opportunistically to identify patients aged 50 years and older who may have low bone mineral density and to prompt clinical bone-health assessment.

Clinical role
Opportunistic low-BMD risk flagging and referral support after radiograph review.
Images and patients
X-ray/Radiography · Lumbar spine, thoracic spine, chest, pelvis, knee, hand, and wrist; low bone-mineral-density screening regions
Key limitation
Keep in mind: The De Novo labeling states that Rho cannot rule out low BMD, absence of a report is not a negative result, and it does not replace DXA or clinical assessment. It is limited to the labeled radiograph types and adults aged 50 years and older.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Rho analyzes standard frontal radiographs opportunistically to identify patients aged 50 years and older who may have low bone mineral density and to prompt clinical bone-health assessment.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Lumbar spine, thoracic spine, chest, pelvis, knee, hand, and wrist; low bone-mineral-density screening regions Input: Standard frontal DICOM radiographs plus patient age and sex.
  • Who uses it?Intended users: Radiologists and referring clinicians or other physician interpreters.
  • What does the software produce?Output: A positive or negative low-BMD report; positive reports are sent to PACS or a browser, while negative reports do not generate an output.
  • What is its most important limitation?Key limitation: The De Novo labeling states that Rho cannot rule out low BMD, absence of a report is not a negative result, and it does not replace DXA or clinical assessment. It is limited to the labeled radiograph types and adults aged 50 years and older.

Clinical takeaway. Clinical role: Rho analyzes standard frontal radiographs opportunistically to identify patients aged 50 years and older who may have low bone mineral density and to prompt clinical bone-health assessment.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective, multi-center study comparing Rho with DXA (low BMD: T-Score <-1.0 at a femoral neck or L1-L4) on 3729 TNI6, 522 OneMedNet and 591 Osteoarthritis Initiative cases. Sensitivity was 0.67 (0.66-0.69), 0.45 (0.41-0.50) and 0.36 (0.31-0.41), and specificity 0.90 (0.88-0.92), 0.93 (0.90-0.96) and 0.94 (0.92-0.96), for TNI, OMN and OAI; sensitivity was comparatively low, while specificity and AUC goals were met in all three datasets. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Rho analyzes standard frontal radiographs opportunistically to identify patients aged 50 years and older who may have low bone mineral density and to prompt clinical bone-health assessment.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Opportunistic low-BMD risk flagging and referral support after radiograph review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Standard frontal DICOM radiographs plus patient age and sex.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
A positive or negative low-BMD report; positive reports are sent to PACS or a browser, while negative reports do not generate an output.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiology and imaging-clinic workflows where standard frontal radiographs are already obtained.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists and referring clinicians or other physician interpreters.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The De Novo labeling states that Rho cannot rule out low BMD, absence of a report is not a negative result, and it does not replace DXA or clinical assessment. It is limited to the labeled radiograph types and adults aged 50 years and older.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports a retrospective, multi-center study comparing Rho with DXA (low BMD: T-Score <-1.0 at a femoral neck or L1-L4) on 3729 TNI6, 522 OneMedNet and 591 Osteoarthritis Initiative cases. Sensitivity was 0.67 (0.66-0.69), 0.45 (0.41-0.50) and 0.36 (0.31-0.41), and specificity 0.90 (0.88-0.92), 0.93 (0.90-0.96) and 0.94 (0.92-0.96), for TNI, OMN and OAI; sensitivity was comparatively low, while specificity and AUC goals were met in all three datasets. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Clinical performance of the device was provided in the form of a retrospective, multi-center study to compare sensitivity and specificity of the device with the gold standard" … "Ground truth low BMD is defmed as at least one of the femoral necks or L1-L4 vertebrae having a T-Score <-1.0 when assessed by DXA.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports a retrospective, multi-center study comparing Rho with DXA (low BMD: T-Score <-1.0 at a femoral neck or L1-L4) on 3729 TNI6, 522 OneMedNet and 591 Osteoarthritis Initiative cases. Sensitivity was 0.67 (0.66-0.69), 0.45 (0.41-0.50) and 0.36 (0.31-0.41), and specificity 0.90 (0.88-0.92), 0.93 (0.90-0.96) and 0.94 (0.92-0.96), for TNI, OMN and OAI; sensitivity was comparatively low, while specificity and AUC goals were met in all three datasets. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Clinical performance of the device was provided in the form of a retrospective, multi-center study to compare sensitivity and specificity of the device with the gold standard" … "Ground truth low BMD is defmed as at least one of the femoral necks or L1-L4 vertebrae having a T-Score <-1.0 when assessed by DXA.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone sensitivity for low BMD by DXA (T-score <-1) on TNI (n=3729): 0.67 (0.66-0.69); OMN (n=513): 0.45 (0.41-0.50); OAI (n=591): 0.36 (0.31-0.41).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "n Sensitivity Specificity AUC group All data split by dataset TNI 3729 0.67 (0.66-0.69) 0.90 (0.88-0.92) 0.88 (0.88-0.90) OMN 513 0.45 (0.41-0.50) 0.93 (0.90-0.96) 0.85 (0.82-0.88) OAI 591 0.36 (0.31-0.41) 0.94 (0.92-0.96) 0.82 (0.79-0.85)" … "Ground truth Low BMD was defined by DXA (at least one of the femoral neck or L1-4 having a T-score <-1).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Standalone specificity for low BMD by DXA (T-score <-1) on TNI (n=3729): 0.90 (0.88-0.92); OMN (n=513): 0.93 (0.90-0.96); OAI (n=591): 0.94 (0.92-0.96).
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "n Sensitivity Specificity AUC group All data split by dataset TNI 3729 0.67 (0.66-0.69) 0.90 (0.88-0.92) 0.88 (0.88-0.90) OMN 513 0.45 (0.41-0.50) 0.93 (0.90-0.96) 0.85 (0.82-0.88) OAI 591 0.36 (0.31-0.41) 0.94 (0.92-0.96) 0.82 (0.79-0.85)" … "Ground truth Low BMD was defined by DXA (at least one of the femoral neck or L1-4 having a T-score <-1).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

TNI6 low-BMD sensitivity

0.67 proportion

  • EndpointLow-BMD classification sensitivity
  • PopulationTNI6 validation dataset
  • Tested versionRho

TNI6 low-BMD specificity

0.9 proportion

  • EndpointLow-BMD classification specificity
  • PopulationTNI6 validation dataset
  • Tested versionRho

OMN low-BMD sensitivity

0.45 proportion

  • EndpointLow-BMD classification sensitivity
  • PopulationOMN validation dataset
  • Tested versionRho

OAI low-BMD sensitivity

0.36 proportion

  • EndpointLow-BMD classification sensitivity
  • PopulationOAI validation dataset
  • Tested versionRho

DEN230023 FDA evidence package for Rho

  • DesignFDA De Novo clinical validation across three radiographic datasets.
  • PopulationTNI6, OMN, and OAI radiographic validation datasets as tabulated in the FDA De Novo review.
  • Scopeexact submission
  • Tested versionRho
  • Sites6
  • IndependenceSponsor or vendor study

DEN230023

FDA tables include TNI6 n=3,729, OMN n=513, and OAI n=591; the De Novo record is the source anchor and linked FDA review contains detailed tables.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched DEN230023 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Standard frontal DICOM radiographs plus patient age and sex.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho

  2. Routing

    Source context, not route validation: The FDA De Novo materials describe DICOM radiograph input, PACS interface, and positive-result delivery to PACS or a browser.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: A positive or negative low-BMD report; positive reports are sent to PACS or a browser, while negative reports do not generate an output.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho

  5. Viewer/worklist/report

    Unresolved route: A positive or negative low-BMD report; positive reports are sent to PACS or a browser, while negative reports do not generate an output.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA De Novo record DEN230023: Rho

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA De Novo materials describe DICOM radiograph input, PACS interface, and positive-result delivery to PACS or a browser.
  • Exact FDA submission
  • Checked 2026-09-04
Training
Use by radiologists and referring clinicians or other physician interpreters. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for DEN230023.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to DEN230023.

exact submission · checked 2026-09-04

Deployment boundary

The exact public deployment boundary is incomplete; confirm hosting, data flow, availability, upgrades, security, service, and downtime locally.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA De Novo materials describe DICOM radiograph input, PACS interface, and positive-result delivery to PACS or a browser.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for DEN230023.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
DEN230023
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Lumbar spine, thoracic spine, chest, pelvis, knee, hand, and wrist; low bone-mineral-density screening regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
De Novo
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-04-09
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-authorized
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. Every record concerns Rho biology or an unrelated clinical intervention and does not identify the 16 Bit Rho device or DEN230023. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda denovo record, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact FDA decision material does not establish complete deployment topology, hosting responsibility, availability, upgrade, or service boundaries.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA De Novo record DEN230023: Rho

    U.S. Food and Drug Administration - Published 2024-04-09 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rho model card (DEN230023)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. DEN230023 FDA decision

    Regulatory record

    De Novo

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253192

DeepXray Spina

Alpha Intelligence Manifolds, Inc.

Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.

Modality
X-ray/Radiography
Anatomy
Spine/Bone Health
Decision
2026-06-10
FDA-cleared K260378

Rayvolve

AZmed

Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.

Modality
X-ray/Radiography
Anatomy
Musculoskeletal and chest/ribs radiographs across specified views
Decision
2026-05-12
FDA-cleared K252953

Velmeni for Dentists (V4D) Endo-Perio

Velmeni, Inc.

Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.

Modality
X-ray/Radiography
Anatomy
Permanent teeth and jaw/maxillofacial anatomy, including enamel, dentine, pulp, root, mental foramen, inferior alveolar canal, maxillary sinus, cementoenamel junction, crestal bone, and root-canal-treated teeth
Decision
2026-05-11
FDA-cleared K251934

qXR-Detect

Qure.Ai Technologies

Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.

Modality
X-ray/Radiography
Anatomy
Chest/Lung; pleura, mediastinum/hila/heart, bone, hardware and other chest-radiograph regions
Decision
2026-01-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history